ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

RFA/PA/Drug Group Announcement Limited

May 6, 1988

Senate Confirms Elias Zerhouni For NIH Director

May 3, 2002

FDA Committee Okays High Dose Methotrexate, Mitxantrone In ANL; reverse Breast Cancer Vote

December 11, 1987

NCCS Networker Volume 9 Issue 1, Spring 1995

April 13, 1995

Henry Neil, Natcher’s right arm, Back In The Job

March 25, 1988

In Brief: Hatch Restores NCI Budget Bypass Authority In His Bill Renewing National Cancer Act

April 23, 1982